TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease ...
The Food and Drug Administration (FDA) has granted Fast Track designation to TRI-611 for the treatment of anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).
FDA fast track designation applies to ALK+ NSCLC progressing after ≥2 ALK TKIs, reflecting limited post-lorlatinib ...
TRI-611 is an oral investigational small molecule therapy designed as a potent, brain-penetrant molecular glue degrader, engaging the body’s innate protein-degradation machinery to target ALK fusion ...
Signia Capital Management, a boutique money management firm that focuses on Small-Micro Cap and Small Cap Value investing, released its fourth-quarter 2025 investor letter for “Signia Small Cap Value ...
This is read by an automated voice. Please report any issues or inconsistencies here. For nearly a century, scientists have chased the “holy grail” of clean power: nuclear fusion. Today, that pursuit ...
As part of its 50 point artificial intelligence (AI) opportunities action plan, the UK government announced that the country’s first AI supercomputer is being established to support Culham Campus in ...
European regulators have backed RET inhibitor and PD-1 regimens, expanding first line options in advanced lung, thyroid, and ...
This TECDOC compiles international experiences and safety practices related to experimental fusion machines. Its objective is to provide an insight into the safety considerations for prototype, ...
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results